BVS Bioventus
Bioventus earnings company data as of 3:59 PM ET 10/23
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 3 Nov | EPS | 0.17 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by BVS's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $312K sold by 2 insiders outside a trading plan
- None no planned (10b5-1) sales
-
Michelle McMurry-Heath DirectorSale$105K 12,000 shares at $8.79 21% of stakeTraded Mar 11 Filed Mar 13
-
Guy P Nohra DirectorSale$76K 10,000 shares at $7.57 7.9% of stakeTraded Dec 4, 2025 Filed Dec 8, 2025
-
Michelle McMurry-Heath DirectorSale$131K 17,701 shares at $7.42 24% of stakeTraded Nov 7, 2025 Filed Nov 10, 2025
Also filed in the last 12 months, not counted as buying or selling: 24 option exercises and 14 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 13 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.02,8.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.